The Korean Journal of Medicine

  • 제84권3호
  • /
  • Pages.346-356
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

폐동맥 고혈압 치료의 최신 지견

Updates on the Treatment of Pulmonary Hypertension

  • 이상은 (연세대학교 의과대학 내과학교실 심장내과) ;
  • 장혁재 (연세대학교 의과대학 내과학교실 심장내과)
  • Lee, Sang-Eun (Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Chang, Hyuk-Jae (Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine)
  • 발행 : 2013.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Pulmonary arterial hypertension (PAH) is a rare and severe clinical condition characterized by luminal obliteration of small pulmonary arteries. It results in increased resistance to pulmonary blood flow, and ultimately, right ventricular failure and death. Although no curative treatments exists for PAH, improved understanding of the pathobiological mechanisms of this disease has resulted in the development of effective therapies that target specific aberrant pathways during the past 20 years. Current treatments including prostanoids, endothelin-1 (ET-1) antagonists, and phosphodiesterase (PDE) inhibitors, have been demonstrated in randomized, controlled studies to confer improvements in functional status, pulmonary hemodynamics, and possibly even slow disease progression. Several alternative pathways believed to play an important role in the pathogenesis of PAH have been identified as potentially useful therapeutic targets and a number of investigative approaches focusing on these targets are under active development. As the number of options available for PAH treatment continues to increase, treatment decisions regarding first-line therapy, combination treatments, and add-on strategies are becoming more complex. This review article focuses on pharmacological agents currently available for the treatment of PAH and discusses potential novel option of treatment strategies.

키워드

참고문헌

  1. McGoon MD, Miller DP. Reveal: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev 2012;21:8-18. https://doi.org/10.1183/09059180.00008211
  2. Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-555. https://doi.org/10.1183/09031936.00057010
  3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301. https://doi.org/10.1056/NEJM199602013340504
  4. Tapson VF, Torres F, Kermeen F. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142:1383-1390. https://doi.org/10.1378/chest.11-2212
  5. National Institutes of Health. Study in subjects with PAH and PH secondary to IPF using inhaled NITROsyl (PHiano) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Jan 14, 2013]. Available from: http://clinicaltrialsgov/ct2/show/NCT01265888.
  6. Rubin L, Pulido T, Channick R, et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN Trial. CHEST 2012;142 (4_MeetingAbstracts):1026A. https://doi.org/10.1378/chest.1456207
  7. National Institutes of Health. Long-term extension study of the SERAPHIN Study, to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension (SERAPHIN OL) [Internet]. Bethesda (MD): National Institutes of Health, c2008 [cited last updated Oct 23, 2012]. Available from: http://clinicaltrials.gov/ct2/show/ NCT00667823.
  8. Simonneau G, Lang I, Torbicki A, et al. Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2010;181:A2515.
  9. National Institutes of Health. ACT-293987 in pulmonary arterial hypertension [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Feb 5, 2013]. Available from: http:// clinicaltrials.gov/ct2/show/NCT01106014? term=GRIPHON&rank=1.
  10. Rubin L, Parikh K, Pulido T, et al. FREEDOM-M: efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension. CHEST 2011;140(4_MeetingAbstracts):1044A. https://doi.org/10.1378/chest.1212098
  11. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013;127:624-633. https://doi.org/10.1161/CIRCULATIONAHA.112.124388
  12. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-799. https://doi.org/10.1183/09031936.00182909
  13. Ghofrani H, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1). CHEST 2012;142(4_MeetingAbstracts):1027A. https://doi.org/10.1378/chest.1462799
  14. National Institutes of Health. BAY63-2521: long-term extension study in patients with pulmonary arterial hypertension (PATENT-2) [Internet]. Bethesda (MD): National Institutes of Health, c2009 [cited last updated Jan 9, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT00863681.
  15. National Institutes of Health. Evaluation of the pharmacodynamic effect of the combination of sildenafil and riociguat on blood pressure and other safety parameters (PATENT PLUS) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Nov 28, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01179334.
  16. National Institutes of Health. A phase 2, multi-center, openlabel study to evaluate the intermediate/long-term safety and efficacy of air001 on subjects with WHO group 1 pulmonary arterial hypertension [Internet]. Bethesda (MD): National Institutes of Health, c2012 [cited last updated Nov 29, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01725269.
  17. Waxman AB, Lawler L, Cornett G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med 2008;168:2164-2166. https://doi.org/10.1001/archinte.168.19.2164
  18. Gomberg-Maitland M, Oudiz R, Shapiro S, et al. Cicletanine as add-on therapy for pulmonary arterial hypertension. CHEST 2012;142(4_MeetingAbstracts):806A. https://doi.org/10.1378/chest.1386552
  19. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-1177. https://doi.org/10.1164/rccm.201001-0123OC
  20. National Institutes of Health. Imatinib (QTI571) in pulmonary arterial hypertension (IMPRES) [Internet]. Bethesda (MD): National Institutes of Health, c2009 [cited last updated Aug 13, 2012]. Available from: http://clinicaltrials.gov/ct2/show/ record/NCT00902174.
  21. National Institutes of Health. Extension to QTI571A2301 to evaluate the long-term safety, tolerability and efficacy of imatinib in severe pulmonary arterial hypertension (IMPRES Extn) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Jan 2, 2013]. Available from: http://clinicaltrials.gov/ ct2/show/NCT01117987.
  22. National Institutes of Health. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Oct 1, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01179737.
  23. National Institutes of Health. Rituximab for treatment of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Nov 28, 2012]. Available from: http://clinicaltrials.gov/ ct2/show/NCT01086540.
  24. Gomberg-Maitland M, Maitland ML, Barst RJ, et al. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2010;87:303-310. https://doi.org/10.1038/clpt.2009.217
  25. Mouchaers KT, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 2010;36: 800-807. https://doi.org/10.1183/09031936.00130209
  26. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011;75:1801-1810. https://doi.org/10.1253/circj.CJ-11-0567
  27. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006;70:174-178. https://doi.org/10.1253/circj.70.174
  28. Fujita H, Fukumoto Y, Saji K, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010;25: 144-149. https://doi.org/10.1007/s00380-009-1176-8
  29. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-288. https://doi.org/10.1172/JCI0216421
  30. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135. https://doi.org/10.1161/01.CIR.97.12.1129
  31. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005;127:1446-1452. https://doi.org/10.1378/chest.127.4.1446
  32. Kawut SM, Bagiella E, Lederer DJ, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011;123:2985-2993. https://doi.org/10.1161/CIRCULATIONAHA.110.015693
  33. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-254. https://doi.org/10.1016/S0002-9343(99)80156-9
  34. O'Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011;8:526-538. https://doi.org/10.1038/nrcardio.2011.104
  35. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-1346. https://doi.org/10.1172/JCI17500
  36. Galie N, Boonstra A, Ewert R, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2010;181:A2516.
  37. Wang XX, Zhang FR, Shang YP, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007;49: 1566-1571. https://doi.org/10.1016/j.jacc.2006.12.037
  38. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-694. https://doi.org/10.1183/09031936.06.00057906
  39. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174: 1257-1263. https://doi.org/10.1164/rccm.200603-358OC
  40. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-1922. https://doi.org/10.1016/j.jacc.2010.01.027
  41. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-530. https://doi.org/10.7326/0003-4819-149-8-200810210-00004
  42. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119: 2894-2903. https://doi.org/10.1161/CIRCULATIONAHA.108.839274
  43. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011;30:632-643. https://doi.org/10.1016/j.healun.2010.11.009
  44. Benza RL, Gupta H, Soto FJ, et al. Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: the COMPASS-3 Study. CHEST 2010;138(4_MeetingAbstracts): 840A. https://doi.org/10.1378/chest.10295
  45. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359. https://doi.org/10.1183/09031936.04.00028404
  46. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012;31:150-158. https://doi.org/10.1016/j.healun.2011.11.002
  47. National Institutes of Health. A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Feb 13, 2013]. Available from: http://clinicaltrials.gov/ct2/ show/study/NCT01178073.
  48. National Institutes of Health. A 48-week study of the effect of dual therapy (inhaled treprostinil and tadafafil) versus monotherapy (tadalafil), 2 FDA approved pulmonary hypertension medications [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Feb 24, 2011]. Available from: http://clinicaltrials. gov/ct2/show/study/NCT01305252.
  49. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010;181:1106-1113. https://doi.org/10.1164/rccm.2009111-699OC
  50. National Institutes of Health. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Nov 3, 2011]. Available from: http://clinicaltrials. gov/ct2/show/NCT01083524.
  51. Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009;4:853-865. https://doi.org/10.1002/cmdc.200900014
  52. National Institutes of Health. Pulmonary hypertension: assessment of cell therapy (PHACeT) [Internet]. Bethesda (MD): National Institutes of Health, c2007 [cited last updated Jun 6, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT 00469027.
  53. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2011;30:93-99.
  54. Oudiz R, Shapiro S, Torres F, et al. ATHENA-1: hemodynamic improvements following the addition of ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension. Chest 2011;140(4_MeetingAbstracts):905A. https://doi.org/10.1378/chest.1113577
  55. National Institutes of Health. Study providing monotherapy (sitaxsentan) and combination therapy (sitaxsentan+sildenafil) to subjects with pulmonary arterial hypertension (PAH) to assess long-term safety [Internet]. Bethesda (MD): National Institutes of Health, c2008 [cited last updated Jan 20, 2012]. Available from: http://clinicaltrials.gov/show/NCT00796510.
  56. National Institutes of Health. Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension (PAH) (compass 2) [Internet]. Bethesda (MD): National Institutes of Health, c2006 [cited last updated Feb 17, 2012]. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00303459?term=compass-2 &rank=1.